Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Perindopril Tert-butylamine Tablets in Healthy Chinese Subjects
NCT04556058Phase 1Completed
- Sponsor
- Sichuan Haisco Pharmaceutical Co., Ltd.
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perindopril tert-butylamine in hypertension (HTN) (2 arms), sponsored by Sichuan Haisco Pharmaceutical Co., Ltd. Primary endpoints: Maximum drug concentration (Cmax) of Perindopril and Area under the plasma concentration versus time curve (AUC0-∞, AUC0-t) of Perindopril. Started Nov 2018; status: completed.
02
Drugs
perindopril tert-butylamine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04556058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556058.